TY - JOUR
T1 - Molecular dynamic simulation analysis on marine fungi compounds against EGFR and VEGFR-2 inhibitory activity in non-small cell lung cancer
AU - Yanuar, Arry
AU - Chavarina, Kinanti Khansa
AU - Syahdi, Rezi Riadhi
N1 - Funding Information:
The authors wish to acknowledge the grants PITTA 2017 provided by the Directorate of Research and Community Engagement, Universitas Indonesia for this study. The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. LigandScout 4.09.2 is licensed to Arry Yanuar, Universitas Indonesia.
Publisher Copyright:
© 2018 EManuscript Technologies. All rights reserved.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Introduction: According to International Agency for Research on Cancer (IARC), the number of lung cancer patients has reached 1.8 million lives, and 85% of the number contribute to non-small cell lung cancer. In the past years, research on targeted therapy has been developed due to its efficacy and a small number of side effects. Research on marine fungi compounds has not been explored to non-small cell lung cancer therapy. Methods: This research uses molecular dynamics simulation method to marine fungi compounds that have been docked to EGFR (FU0015, FU0051, FU0202) and VEGFR-2 (FU0033) as antiproliferative and antiangiogenetic agent by inhibition activity using AutoDock and AMBER at 300K and 310K temperature using EGFR (Gefitinib, Erlotinib, and Imatinib) and VEGFR-2 (Nicotinamide and Vatalanib) as reference standards. Results: Molecular dynamics results for EGFR inhibitors at 310K shows the best MMGBSA free energy and hydrogen occupancy in FU0051 (-43.72 kcal/mol; 98.80%) followed by FU0202 (-31.64 kcal/mol; 43.35%), and FU0015 (-15.55 kcal/mol; 3.35%). FU0033 fungi as a material for VEGFR-2 inhibitor shows higher MMGBSA free energy in comparison to its reference standards and low hydrogen occupancy (0.15%) at 310K. Conclusion:This research shows that FU0051 and FU0202 have potential to be an antiproliferative agent candidate, hence in vitro test should be obtained.
AB - Introduction: According to International Agency for Research on Cancer (IARC), the number of lung cancer patients has reached 1.8 million lives, and 85% of the number contribute to non-small cell lung cancer. In the past years, research on targeted therapy has been developed due to its efficacy and a small number of side effects. Research on marine fungi compounds has not been explored to non-small cell lung cancer therapy. Methods: This research uses molecular dynamics simulation method to marine fungi compounds that have been docked to EGFR (FU0015, FU0051, FU0202) and VEGFR-2 (FU0033) as antiproliferative and antiangiogenetic agent by inhibition activity using AutoDock and AMBER at 300K and 310K temperature using EGFR (Gefitinib, Erlotinib, and Imatinib) and VEGFR-2 (Nicotinamide and Vatalanib) as reference standards. Results: Molecular dynamics results for EGFR inhibitors at 310K shows the best MMGBSA free energy and hydrogen occupancy in FU0051 (-43.72 kcal/mol; 98.80%) followed by FU0202 (-31.64 kcal/mol; 43.35%), and FU0015 (-15.55 kcal/mol; 3.35%). FU0033 fungi as a material for VEGFR-2 inhibitor shows higher MMGBSA free energy in comparison to its reference standards and low hydrogen occupancy (0.15%) at 310K. Conclusion:This research shows that FU0051 and FU0202 have potential to be an antiproliferative agent candidate, hence in vitro test should be obtained.
KW - EGFR
KW - Lung cancer
KW - Marine fungi compounds
KW - Molecular dynamics
KW - VEGFR-2
UR - http://www.scopus.com/inward/record.url?scp=85050266448&partnerID=8YFLogxK
U2 - 10.5530/jyp.2018.2s.6
DO - 10.5530/jyp.2018.2s.6
M3 - Article
AN - SCOPUS:85050266448
SN - 0975-1483
VL - 10
SP - s25-s31
JO - Journal of Young Pharmacists
JF - Journal of Young Pharmacists
IS - 2
ER -